Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2008

01-02-2008 | Epidemiology

Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk

Authors: Yong Zhu, Richard G. Stevens, Derek Leaderer, Aaron Hoffman, Theodore Holford, Yawei Zhang, Heather N. Brown, Tongzhang Zheng

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Login to get access

Abstract

Three known non-synonymous polymorphisms (Ala394Thr, Ser471Leu and Pro690Ala) in the largest circadian gene, Neuronal PAS domain protein 2 (NPAS2), were genotyped in a breast cancer case-control study conducted in Connecticut, USA (431 cases and 476 controls). We found that women with the heterozygous Ala394Thr genotype were significantly associated with breast cancer risk compared to those with the common homozygous Ala394Ala (OR = 0.61, 0.46–0.81, P = 0.001). This is the first evidence demonstrating a role of the circadian gene NPAS2 in human breast cancer, suggesting that genetic variations in circadian genes might be a novel panel of biomarkers for breast cancer risk.
Literature
1.
Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562PubMedCrossRef
2.
Schernhammer ES, Laden F, Speizer FE et al (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 93:1563–1568PubMedCrossRef
3.
Lie JA, Roessink J, Kjaerheim K (2006) Breast cancer and night work among Norwegian nurses. Cancer Causes Control 17:39–44PubMedCrossRef
4.
Stevens RG (2005) Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 16:254–258PubMedCrossRef
5.
Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3:350–361PubMedCrossRef
6.
Vitaterna MH, King DP, Chang AM et al (1994) Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 264:719–725PubMedCrossRef
7.
Bunger MK, Wilsbacher LD, Moran SM et al (2000) Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 103:1009–1017PubMedCrossRef
8.
Dudley CA, Erbel-Sieler C, Estill SJ et al (2003) Altered patterns of sleep and behavioral adaptability in NPAS2-deficient mice. Science 301:379–383PubMedCrossRef
9.
Zheng T, Holford TR, Mayne ST et al (2000) Risk of female breast cancer associated with serum polychlorinated biphenyls and 1,1-dichloro-2,2’-bis(p-chlorophenyl)ethylene. Cancer Epidemiol Biomarkers Prev 9:167–174PubMed
10.
Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T (2005) Period3 Structural Variation: A circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 14:268–270PubMed
11.
Fu L, Pelicano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41–50PubMedCrossRef
12.
Johansson C, Willeit M, Smedh C et al (2003) Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 28:734–739PubMedCrossRef
13.
Lam RW, Levitan RD (2000) Pathophysiology of seasonal affective disorder: a review. J Psychiatry Neurosci 25:469–480PubMed
14.
Zhu Y, Leaderer D, Guss C et al (2007) Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin’s lymphoma. Int J Cancer 120:432–435PubMedCrossRef
15.
Walters JF, Hampton SM, Deanfield JE et al (2006) Circadian variation in endothelial function is attenuated in postmenopausal women. Maturitas 54:294–303PubMedCrossRef
16.
Koyanagi S, Kuramoto Y, Nakagawa H et al (2003) A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res 63:7277–7283PubMed
17.
Wood PA, Du-Quiton J, You S, Hrushesky WJ (2006) Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 5:2023–2033PubMedCrossRef
18.
Hrushesky WJ, Bluming AZ, Gruber SA, Sothern RB (1989) Menstrual influence on surgical cure of breast cancer. Lancet 2:949–952PubMedCrossRef
19.
Retsky M, Demicheli R, Hrushesky W (2001) Breast cancer screening for women aged 40–49 years: screening may not be the benign process usually thought. J Natl Cancer Inst 93:1572PubMed
20.
Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298PubMedCrossRef
Metadata
Title
Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk
Authors
Yong Zhu
Richard G. Stevens
Derek Leaderer
Aaron Hoffman
Theodore Holford
Yawei Zhang
Heather N. Brown
Tongzhang Zheng
Publication date
01-02-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9565-0

Other articles of this Issue 3/2008

Breast Cancer Research and Treatment 3/2008 Go to the issue

Preclinical Study

Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility

Epidemiology

Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients

Preclinical Study

Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea

Epidemiology

Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations

Letter to the Editor

Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case–control study and a pooled meta-analysis

Epidemiology

Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits